The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Endocrinology"
DOI: 10.3389/fendo.2022.1033479
Abstract: Since type 2 diabetes mellitus (T2DM) is a risk factor for Alzheimer’s disease (AD) and both have the same pathogenesis (e.g., insulin resistance), drugs used to treat T2DM have been gradually found to reduce the… read more here.
Keywords: mechanism efficacy; disease; alzheimer disease; glp agonists ... See more keywords